ORLANDO — Two first-in-class molecules from EyeBio have shown promising results for the treatment of retinal diseases, according to a presenter at Eyecelerator@AAO.
Restoret (MK-3000) is an antibody that activates Wnt in the retinal vasculature, Anthony P. Adamis, MD, chief scientific officer and cofounder of EyeBio, told Healio.
“Wnt is necessary for both the development and the maintenance of the blood-retinal barrier, and the hope was that by agonizing this pathway, we would get rid of excess fluid in diseases like diabetic macular edema,” he said.
In a phase 1b/2a clinical trial that